Toll-Like receptor 4 signaling mediates inflammatory activation induced by c-reactive protein in vascular smooth muscle cells

Cellular Physiology and Biochemistry

Volumn 25, Issue 4-5, 2010, Pages 467-476

  Liu, Na ^a   Liu, Juntian ^a   Ji, Yuanyuan ^a   Lu, Peipei ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Toll like receptor 4; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; C REACTIVE PROTEIN; GLUCOCORTICOID RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROTEIN KINASE C ALPHA; TOLL LIKE RECEPTOR 4; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; INFLAMMATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

RATTUS;

EID: 77949988816     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000303052     Document Type: Article

References (40)

1. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
2. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-771.
3. Verma S, Devaraj S, Jialal I: Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006;113:2135-2150.
4. Pasceri V, Willerson JT, Yeh ETH: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
5. Hattori Y, Matsumura M, Kasai K: Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003;58:186-195.
6. Ballou SP, Lozanski G: Induction of inflammatory cytokine release from cultured human monocytes by CRP. Cytokine 1992;4:361-368.
7. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J: C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-2099.
8. Warrier B, Mallipeddi R, Karla PK, Lee CH: The functional role of C-reactive protein in aortic wall calcification. Cardiology 2005;104:57-64.
9. Yeh ET, Anderson HV, Pasceri V, Willerson JT: C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001;104:974-975.
10. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:1876-1890.
11. Miggin SM, O'Neill LA: New insights into the regulation of TLR signaling. J Leukoc Biol 2006;80:220-226.
12. O'Neill LA: Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 2003;3:396-403.
13. Edfeldt K, Swedenborg J, Hansson GK, Yan Z: Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002;105:1158-1160.
14. Faure E, Thomas L, Xu H, Medvedev AE, Equils O, Arditi M: Bacterial lipopolysaccharide and IFN-gamma induce toll-like receptor 2 and toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001;166:2018-2024.
15. Ong KG, Leland JM, Zeng K, Barrett G, Zourob M, Grimes CA: A rapid highly-sensitive endotoxin detection system. Biosens Bioelectron 2006;21:2270-2274.
16. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G: A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 1986;103:2787-2796.
17. Heerkens EH, Shaw L, Ryding A, Brooker G, Mullins JJ, Austin C, Ohanian V, Heagerty AM: aV integrins are necessary for eutrophic inward remodeling of small arteries in hypertension. Hypertension 2006;47:281-287.
18. Granger DL, Taintor RR, Boockvar KS, Hibbs JB Jr: Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol 1996;268:142-151.
19. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using realtime quantitative PCR and the DDCT Method. Methods 2001;25:402-408.
20. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA Jr, Yasukochi Y, Numano F: HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001;21:1165-1171.
21. Chen CC, Wang JK, Lin SB: Antisense oligonucleotides targeting protein kinase C-a,-pI, or-8 but Not-r| inhibit lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages: involvement of a nuclear factor KB-dependent mechanism. J Immunol 1998;161:6206-6214.
22. Park JY, Kim YM, Song HS, Park KY, Kim YM, Kim MS, Pak YK, Lee IK, Lee JD, Park SJ, Lee KU: Oleic acid induces endothelin-1 expression through activation of protein kinase C and NF-KB. Biochem Biophys Res Commun 2003;303:891-895.
23. Yang X, Coriolan D, Murthy V, Schultz K, Golenbock DT, Beasley D: Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. Am J Physiol Heart Circ Physiol 2005;289:H1069-H1076.
24. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
25. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996;2:992-997.
26. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY: Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001;276:7614-7620.
27. Panutsopulos D, Papalambros E, Sigala F, Zafiropoulos A, Arvanitis DL, Spandidos DA: Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions. Int J Mol Med 2005;15:603-610.
28. Dulak J, Jozkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D, Florek I, Wójtowicz A, Szuba A, Cooke JP: Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:659-666.
29. Depre C, Havaux X, Renkin J, Vanoverschelde JLJ, Wijns W: Expression of inducible nitric oxide synthase in human coronary atherosclerotic plaque. Cardiovasc Res 1999;41:465-472.
30. Radomski MW, Salas E: Nitric oxide-biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis 1995;118:S69-S80.
31. Ratnam S, Mookerjea S: The regulation of superoxide generation and nitric oxide synthesis by C-reactive protein. Immunology 1998;94:560-568.
32. Heck S, Bender K, Kullmann M, Göttlicher M, Herrlich P, Cato AC: IKBOI-independent downregulation of NF-KB activity by glucocorticoid receptor. EMBO J 1997;16:4698-4707.
33. Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, Gerritsen ME, Collins T: Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 1998;273:29291-29294.
34. Hill MR, Stith RD, McCallum RE: Human recombinant IL-1 alters glucocorticoid receptor function in Reuber hepatoma cells. J Immunol 1988;141:1522-1528.
35. Amaya K, Ohta T, Kitagawa H, Kayahara M, Takamura H, Fujimura T, Nishimura G, Shimizu K, Miwa K: Angiotensin II activates MAP kinase and NF-KB through angiotensin II type I receptor in human pancreatic cancer cells. Int J Oncol 2004;4:849-856.
36. Ji YY, Liu JT, Wang ZD, Liu N: Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2009;23:265-276.
37. Lin FY, Chen YH, Tasi JS, Chen JW, Yang TL, Wang HJ, Li CY, Chen YL, Lin SJ: Endotoxin induces toll-like receptor 4 expression in vascular smooth muscle cells via NADPH oxidase activation and mitogen-activated protein kinase signaling pathways. Arterioscler Thromb Vasc Biol 2006;26:2630-2637.
38. Wang CH, Li SH, Weisel RD, Fedak PWM, Dumont AS, Szmitko P, Li RK, Mickle DAG, Verma S: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-1790.
39. Takeda K, Akira S: Toll-like receptors in innate immunity. Int Immunol 2005;17:1-14.
40. Rhee SH, Hwang D: Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J Biol Chem 2000;275:34035-34040.